Canaccord raised the firm’s price target on Privia Health (PRVA) to $34 from $32 and keeps a Buy rating on the shares. The firm said its thesis on the copany is playing out as the Q3 beat was strong across the board and management noted that 3Q capitated results would likely be the high-water mark for 2025 as there was retroactive timing of data that contributed to the strength.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PRVA: